GeoVax Plans Phase 2 Trial For Gedeptin Therapy In First-Recurrence Head & Neck Cancer With Immune Checkpoint Inhibitor
Portfolio Pulse from Benzinga Newsdesk
GeoVax plans a Phase 2 trial for its Gedeptin therapy in first-recurrence head and neck cancer with an immune checkpoint inhibitor. The review of the Phase 1b/2a trial shows acceptable safety and efficacy, with no new safety signals identified. Tumor stabilization and reduction support continued development.
July 31, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeoVax plans a Phase 2 trial for its Gedeptin therapy in first-recurrence head and neck cancer with an immune checkpoint inhibitor. The review of the Phase 1b/2a trial shows acceptable safety and efficacy, with no new safety signals identified. Tumor stabilization and reduction support continued development.
The announcement of a Phase 2 trial and positive results from the Phase 1b/2a trial are likely to boost investor confidence in GeoVax. The absence of new safety signals and evidence of tumor stabilization/reduction are positive indicators for the continued development of Gedeptin therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100